A5056906070- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Management of metastatic bone disease
- Cancer Diagnosis and Treatment
- Reconstructive Surgery and Microvascular Techniques
- Musculoskeletal synovial abnormalities and treatments
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Orthopaedic implants and arthroplasty
- Bone fractures and treatments
- Protein Degradation and Inhibitors
- Oral and Maxillofacial Pathology
- Surgical site infection prevention
- Bone health and treatments
- Total Knee Arthroplasty Outcomes
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- CAR-T cell therapy research
- Advanced Chemical Physics Studies
- Pelvic and Acetabular Injuries
- Orthopedic Infections and Treatments
- Lung Cancer Treatments and Mutations
- Soft tissue tumor case studies
- Shoulder Injury and Treatment
- HER2/EGFR in Cancer Research
The University of Texas MD Anderson Cancer Center
2016-2025
Musculoskeletal Transplant Foundation
2024
The University of Texas Health Science Center at Houston
2022
American Academy of Orthopaedic Surgeons
2022
Orthopedic One
2019
Society of Surgical Oncology
2005-2018
Wallace Laboratories
2018
Clinical Orthopaedics and Related Research
2018
Cancer Support Community
2018
Committee on Publication Ethics
2018
Abstract Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors, we conducted whole genome, RNA, and T-cell receptor sequencing, immunohistochemistry reverse phase protein array profiling (RPPA) on OS specimens from 48 pediatric adult primary, relapsed, metastatic OS. Median infiltrate level was lower than other tumor types where ICI are effective, concomitant low...
Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases.To assess relative efficacy of high-dose, single-fraction stereotactic body (SBRT) vs standard multifraction (MFRT) alleviation pain in patients with mostly nonspine metastases.This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 radiologically confirmed painful metastases from September 19, 2014,...
Correlations between various patient, tumor, and treatment characteristics complications in patients undergoing combined modality for primary lower extremity soft-tissue sarcomas were investigated.Using the M. D. Anderson Radiation Oncology database, records of subset treated with radiation limb-sparing surgery retrospectively reviewed from years 1960 to 2003.In all, 412 identified. With a median follow-up 9.3 years, there total 113 (27%) acute wound 41 (13% at 20 years) chronic...
The aim of our study was to retrospectively evaluate whether maximum standardized uptake value (SUV(max)), total lesion glycolysis (TLG), or change therein using (18)F-FDG PET/CT performed before and after initial chemotherapy were indicators patient outcome.Thirty-one consecutive patients who underwent chemotherapy, followed by tumor resection, reviewed. Univariate Cox regression used analyze for relationships between covariates interest (SUV(max) in SUV(max), TLG TLG, necrosis)...
Background: Skeletal metastases from renal cell carcinoma are highly destructive vascular lesions. They pose unique surgical challenges due to the risk of life-threatening hemorrhage and resistance other treatments. The goal this retrospective study was evaluate factors that may affect survival after treatment carcinoma. Methods: We performed a review series 295 consecutive patients who had been treated for metastatic at one institution between 1974 2004. There were 226 men sixty-nine women....
Soft tissue sarcomas are a heterogeneous and rare group of solid tumors mesenchymal origin that can arise anywhere in the body. Although surgical resection is mainstay treatment for patients with localized disease, disease recurrence common 5-year overall survival poor (~ 65%). Both radiation therapy conventional chemotherapy used to reduce local distant recurrence. However, utility often limited by location (in case retroperitoneal sarcomas, instance) while systemic lines offer efficacy...
Reconstruction of the proximal femur after tumor resection can be achieved with either an endoprosthesis or allograft-prosthetic composite. We compared two modalities for complications, functional outcome, and construct survival. retrospectively analyzed 52 patients endoprostheses 20 composite reconstructions between 1974 2002. Median followup was 146 months 76 months, respectively. Both methods were associated low rates early complications. Infections occurred in one patient reconstruction....
In Brief Objective: We conducted a prospective trial to define the local recurrence rates for selected patients with T1 soft tissue sarcomas (STS) treated by surgery alone. Summary Background Data: Retrospective data suggest that some small STS can be safely There are no defined criteria select such treatment. Methods: Patients primary were function-preserving and microscopic assessment of surgical margins. Postoperative external-beam radiation was employed selectively microscopically...
Chondroblastoma is an aggressive tumor of bone with the capacity for recurrence and metastasis. We sought to determine prognostic factors that affect survival local particular emphasis on surgical technique anatomic constraints open physis. It was hypothesized growth plate would impact rate negatively be a primary determinant treatment outcome. retrospectively reviewed 82 consecutive patients treated at one institution. Intralesional meticulous curettage graft resulted in control majority...
Chondrosarcoma is the second most common primary bone tumor, with >90% of cases representing conventional subtype. In addition to arising de novo, chondrosarcoma can arise secondary a benign underlying lesion, such as enchondroma or osteochondroma. Symptoms are often characterized by focal, dull, aching pain affected region. Grade well-recognized prognostic factor in these tumors. I lesions/atypical cartilaginous tumors rarely metastasize, recur, and have 10-year survival rate >80%. By...
The argon beam coagulator is gaining popularity as an adjuvant therapy for treatment of giant cell tumors bone. However, the effectiveness and functional implications this have not been assessed. To determine whether could be a viable option, we examined recurrence rate outcome patients with who were treated coagulator, to curettage cementation. Thirty-seven received coagulation diagnosed between 1993 2000 identified. median age was 32 years (range, 16-64 years). mean followup 73.7 months...